A RANDOMIZED PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF VANDETANIB (ZD6474, ZACTIMATM) VERSUS VINORELBINE IN PATIENTS WITH INOPERABLE OR RELAPSED MALIGNANT MESOTHELIOMA

Update Il y a 5 ans
Reference: EUCTR2007-003633-16

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the efficacy of oral vandetanib 300 mg once daily compared with vinorelbine administrated intravenously weekly in patients with inoperable or relapsed malignant mesothelioma by estimating the overall disease control rate (DCR=CR+PR+SD)


Inclusion criteria

  • Malignant Mesothelioma

Links